Back to Search
Start Over
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
- Source :
-
Diabetes care [Diabetes Care] 2015 Mar; Vol. 38 (3), pp. 376-83. Date of Electronic Publication: 2014 Oct 28. - Publication Year :
- 2015
-
Abstract
- Objective: This study compared the efficacy and safety of dual add-on of saxagliptin plus dapagliflozin versus saxagliptin and dapagliflozin added on alone in patients with type 2 diabetes poorly controlled with metformin.<br />Research Design and Methods: This was a double-blind trial in adults with HbA1c ≥8.0% and ≤12.0% (64-108 mmol/mol), randomized to saxagliptin (SAXA) (5 mg/day) plus dapagliflozin (DAPA) (10 mg/day; n = 179), or SAXA (5 mg/day) and placebo (n = 176), or DAPA (10 mg/day) and placebo (n = 179) on background metformin extended release (MET) ≥1,500 mg/day. Primary objective compared changes from baseline in HbA1c with SAXA+DAPA+MET versus SAXA+MET and DAPA+MET.<br />Results: Patients had a mean baseline HbA1c of 8.9% (74 mmol/mol), diabetes duration of 7.6 years, and a BMI of 32 kg/m(2). At week 24, the adjusted mean change from the baseline HbA1c was -1.5% (-16.1 mmol/mol) with SAXA+DAPA+MET versus -0.9% (-9.6 mmol/mol) with SAXA+MET (difference -0.59% [-6.4 mmol/mol], P < 0.0001) and -1.2% (-13.1 mmol/mol) with DAPA+MET (difference -0.27% [3.0 mmol/mol], P < 0.02). The proportion of patients achieving HbA1c <7% (53 mmol/mol) was 41% with SAXA+DAPA+MET versus 18% with SAXA+MET and 22% with DAPA+MET. Urinary and genital infections occurred in ≤1% of patients receiving SAXA+DAPA+MET. Hypoglycemia was infrequent, with no episodes of major hypoglycemia.<br />Conclusions: In this first report of adding a well-tolerated combination of saxagliptin plus dapagliflozin to background metformin therapy in patients poorly controlled with metformin, greater improvements in glycemic control were obtained with triple therapy by the dual addition of saxagliptin and dapagliflozin than dual therapy with the addition of saxagliptin or dapagliflozin alone.<br /> (© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.)
- Subjects :
- Adamantane administration & dosage
Adamantane adverse effects
Adult
Aged
Benzhydryl Compounds adverse effects
Blood Glucose metabolism
Diabetes Mellitus, Type 2 blood
Dipeptides adverse effects
Double-Blind Method
Drug Therapy, Combination
Female
Glucosides adverse effects
Humans
Hypoglycemia chemically induced
Male
Metformin adverse effects
Middle Aged
Treatment Outcome
Urinary Tract Infections chemically induced
Adamantane analogs & derivatives
Benzhydryl Compounds administration & dosage
Blood Glucose drug effects
Diabetes Mellitus, Type 2 drug therapy
Dipeptides administration & dosage
Glucosides administration & dosage
Metformin administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1935-5548
- Volume :
- 38
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Diabetes care
- Publication Type :
- Academic Journal
- Accession number :
- 25352655
- Full Text :
- https://doi.org/10.2337/dc14-1142